three strengths of Cinacalcet Hydrochloride Tablets (30 mg, 60 mg,…

Regulatory Event

Cipla USA, Inc. has recalled three strengths of Cinacalcet Hydrochloride Tablets (30 mg, 60 mg, and 90 mg, manufactured by Cipla Ltd. at its Patalganga, India facility) under a Class II classification confirmed by FDA on July 9, 2026. The firm initiated the recall on June 29, 2026, covering roughly 31,800-plus bottles distributed nationwide in the United States. The reason for recall, stated identically across all three strengths, is “cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).”

It is worth being precise about why this recall reads differently than a routine potency, foreign-matter, or labeling finding, even though it carries the same Class II designation. N-nitroso-cinacalcet is a nitrosamine impurity — a class of compounds classified as probable or possible human carcinogens based on animal carcinogenicity data, which is why regulatory agencies set an acceptable daily intake limit rather than a simple pass/fail specification threshold, consistent with the risk-based framework in ICH M7 for mutagenic impurities. A finding above the ADI does not mean every patient who took the affected lots faces a defined excess cancer risk; it means the manufacturer’s own control strategy did not keep a known-risk impurity within the limit that regulatory toxicology has established as acceptable for chronic dosing, and FDA’s classification reflects that gap in control rather than a confirmed clinical harm.

What the Record Documents

Nitrosamine contamination in finished oral solid dosage products typically traces back to one or more of three sources: the active pharmaceutical ingredient synthesis route itself, where certain reagents, catalysts, or reaction conditions can generate nitrosamines as unintended by-products; cross-contamination from shared manufacturing equipment or from nitrite-containing excipients or packaging components reacting with secondary or tertiary amines in the drug substance; or a degradation pathway that forms the nitrosamine after manufacture, during storage, under specific temperature, humidity, or nitrite-exposure conditions. Cinacalcet’s chemical structure includes a secondary amine group, which is exactly the structural feature that makes nitrosamine formation plausible under nitrite exposure, whether from a raw material, an excipient, or an upstream synthesis step — this is not a generic degradation risk shared equally by all oral solid dosage products, and a control strategy for this molecule needs to specifically evaluate that amine’s reactivity, not rely on a generic impurity-screening panel designed for other structural classes.

The industry-wide precedent for this failure mode is the valsartan nitrosamine crisis that began in July 2018, when Zhejiang Huahai Pharmaceutical’s valsartan active pharmaceutical ingredient, manufactured in Linhai, China, was found to contain N-nitrosodimethylamine (NDMA) traced to a change in the manufacturing process’s solvent recovery and reaction conditions. That finding triggered a cascading set of recalls across valsartan, losartan, and irbesartan products from multiple manufacturers worldwide, and directly led to FDA’s 2020 (revised 2021 and 2023) Guidance for Industry, Control of Nitrosamine Impurities in Human Drugs, which now sets the expectation that manufacturers conduct a structure-based nitrosamine risk assessment for every drug substance and, where risk is identified, implement confirmatory testing and, where necessary, a revised control strategy. The cinacalcet finding here is a smaller-scale instance of the same underlying control-strategy gap that guidance was written to close.

Technical and Quality Context

21 CFR § 211.192 requires production and control record review before batch release, and for a molecule with a known structural nitrosamine risk, that review needs a validated, sufficiently sensitive analytical method — generally LC-MS/MS given the low-ppm-to-ppb detection limits nitrosamine ADIs require — applied at a testing frequency and sampling point that would catch formation occurring either during synthesis or during storage, not only at initial release. FDA’s ongoing nitrosamine risk-assessment initiative, which has driven confirmatory testing requirements across multiple drug classes since 2018, sets the expectation that manufacturers proactively evaluate nitrosamine formation risk for any molecule with amine-containing structural features, rather than wait for a confirmatory testing mandate specific to that molecule. Whether Cipla’s control strategy for cinacalcet included this kind of structure-based risk evaluation prior to this event, or whether nitrosamine testing was only introduced reactively, is a fair question for FDA’s inspection follow-up to answer, and is generally the kind of gap a robust control strategy — as distinct from a testing strategy alone — is meant to prevent.

No current Warning Letter or Import Alert specific to Cipla’s Patalganga Unit II facility was identified in connection with this event; Cipla’s most recent major FDA Warning Letter on record was issued to a different Indian manufacturing site (Pithampur, dated 2023), so this recall should not be read as part of a same-site enforcement pattern without further verification. It is also worth noting, as a footnote rather than a trend claim, that Amgen’s cinacalcet product (Sensipar) was separately recalled roughly six weeks earlier for unrelated Current Good Manufacturing Practice (CGMP) deviations describing foreign matter, not a nitrosamine finding — two cinacalcet recalls in close succession from different manufacturers, but with different root causes, and that distinction matters more than the coincidence of timing.

Decision Relevance

Any manufacturer producing an oral solid dosage product with a secondary or tertiary amine in its structure should independently verify, rather than assume from a prior clean submission history, that its nitrosamine risk assessment specifically evaluated that structural feature against current agency guidance, that its analytical method for nitrosamine detection is validated to the sensitivity the applicable ADI requires, and that testing occurs both at release and on a stability-indicating schedule sufficient to catch storage-related formation. Quality directors overseeing legacy ANDA products approved before the nitrosamine risk-assessment initiative matured should treat this recall as a prompt to confirm, rather than assume, that their own post-approval nitrosamine risk assessments were completed with the same rigor being applied to new applications today.

This is precisely the kind of control-strategy gap XGene Consulting is engaged to close: nitrosamine risk assessment for existing and new molecular structures, analytical method development and validation for trace-level genotoxic impurity detection, and control strategy design that addresses formation risk at the synthesis, formulation, and storage stages rather than relying on release testing alone. If your product portfolio includes amine-containing molecules and you have not completed a current, structure-specific nitrosamine risk assessment, that gap is worth closing before FDA’s inspection schedule reaches your facility, not after.